Continuously updated topic dossier

Rapamycin

Research concerning mTOR inhibition, rapalogs, ageing biology, and human translation.

Checking source freshness…
Automated evidence frame

Can mTOR modulation improve human healthspan without unacceptable immunological or metabolic risk?

How this is generated

Current evidence state

Human longevity evidence remains incomplete; registered studies and disease-specific evidence should not be treated as proof of lifespan extension.

Known limits

Dose, schedule, population, long-term safety, and clinically meaningful endpoints remain unresolved for longevity use.

Regulatory context

No longevity indication is established by the records indexed here.

Building the latest evidence view…